Group shot of M7824. M7824, an investigational bifunctional immunotherapeutic, was discovered and developed in-house by a team of scientists and medical thought leaders at Merck. Pictured above are members of the M7824 research team located in Billerica, Massachusetts, US

Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers